Plasma interleukin-18 reflects severity of ulcerative colitis

Alicja Wiercinska-Drapalo, Robert Flisiak, Jerzy Jaroszewicz, Danuta Prokopowicz

Alicja Wiercinska-Drapalo, Robert Flisiak, Jerzy Jaroszewicz, Danuta Prokopowicz, Department of Infectious Diseases, Intestinal Diseases Unit, Medical University of Białystok, Zurawia str. 14, 15-540 Białystok, Poland

Correspondence to: Dr. Alicja Wiercinska-Drapalo, Department of Infectious Diseases, Intestinal Diseases Unit, Medical University of Białystok, Zurawia str. 14, 15-540 Białystok, Poland. alicja@poczta.onet.pl

Telephone: +48-85-7416921 Fax: +48-85-7416921

Received: 2004-03-03 Accepted: 2004-04-29

Abstract

AIM: The aim of this study was to evaluate the association between ulcerative colitis activity and plasma or mucosal concentrations of interleukin (IL)-18.

METHODS: IL-18 concentrations were measured in plasma and mucosal samples from 15 patients with active ulcerative colitis (UC).

RESULTS: The mean plasma concentration of IL-18 measured in all patients (422±88 pg/mL) doubled the mean value in healthy controls (206±32 pg/mL); however, the difference was not statistically significant. Plasma IL-18 levels revealed a significant positive correlation with scored endoscopic degree of mucosal injury, disease activity index, clinical activity index and C-reactive protein concentration. The mean concentration of plasma IL-18 was significantly higher in patients with severe ulcerative colitis (535±115 pg/mL) than in patients with mild ulcerative colitis (195±41 pg/mL), and in healthy controls. Although the mucosal mean IL-18 concentration in severe ulcerative colitis (2 523±618 pg/mg protein) doubled values observed in mild one (1 347±308 pg/mg protein), there was no statistically significant difference.

CONCLUSION: Plasma IL-18 can be considered as a surrogate marker helpful in evaluation of ulcerative colitis activity.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

Key words: Ulcerative colitis; Interleukin-18

Wiercinska-Drapalo A, Flisiak R, Jaroszewicz J, Prokopowicz D. Plasma interleukin-18 reflects severity of ulcerative colitis. World J Gastroenterol 2005; 11(4): 605-608

http://www.wjgnet.com/1007-9327/11/605.asp

INTRODUCTION

The pathogenesis of ulcerative colitis (UC) is still unknown, but it seems to be related to the abnormal immune response and diminished ability of mucosal protection and regeneration. Signaling between epithelial cells, involving the complex network of bioactive substances plays a crucial role in these processes[1-4]. Cytokines are involved in the modulation of the immune system related to the pathogenesis of inflammatory bowel disease[5-7], and are rapidly synthesized and secreted by inflammatory cells upon stimulation. They induce the production of adhesion molecules, reactive oxygen metabolites, prostaglandins, leukotrienes, nitric oxide and platelet activating factors. Interleukin (IL)-18 is a potent inducer of interferon gamma production and plays an important role in inducting of both Th1 and Th2 immune responses[8,9]. According to a recent study by Ishikura et al[10], its excessive production could exacerbate colitis in an experimental model. On the other hand, we know from a previous research by Siegmund et al[11], that neutralization of IL-18 with specific antibodies could reduce the severity of experimental colitis. Elevated serum concentration of IL-18 has recently been demonstrated in humans with Crohn’s disease (CD)[12]. The role of IL-18 in the pathogenesis of inflammatory bowel diseases (IBD) was studied mostly in experimental models. The aim of this study was to evaluate the association between ulcerative colitis activity and plasma or mucosal concentrations of interleukin-18.

MATERIALS AND METHODS

Patients

Interleukin-18 concentrations were measured in plasma and mucosal samples from 15 patients (3 females and 12 males) with active ulcerative colitis (UC), aged from 22 to 71 years (mean: 38.9±3.3 years). All patients had a history of diagnosed ulcerative colitis, which required typical clinical and endoscopical signs of distal part bowel involvement. Patients were treated with 5-ASA derivates in the standard dose of 3.0 g/24 h. None of them received any steroids at the time of the study. IL-18 plasma and mucosal concentrations were compared with endoscopic pictures scored according to Meyers et al[13], the disease activity index (DAI) according to Schroeder et al[14], clinical activity index (CAI) according to Truelove and Witts[15]. Routine laboratory indices of the inflammatory process such as C-reactive protein (CRP), sedimentation rate (SR), white blood count (WBC) and platelet count (PLT) as well as hemoglobin, fibrinogen, total protein and albumin concentrations were also measured and compared with IL-18 values. Mucosal biopsy for histological confirmation of UC and for IL-18 measurement was taken during sigmoidoscopy performed before treatment. Patients were divided into two groups with respect to severity of the disease. They were included into the severe UC group if the values of endoscopic score, DAI and CAI exceeded the middle range of all three scales that were 8, 6, 10. Severe form of ulcerative colitis was diagnosed in 10 patients and mild one in 5. Plasma IL-18 concentrations were also compared with those in 12 healthy volunteers (5 females and 7 males with a mean age of 40.8±2.7 years). The study was approved by the Bioethical Committee of the Medical University of Białystok. Informed consent was obtained from each patient.

IL-18 measurement

Venous blood was collected on ice using vacutainer tubes with...
K-EDTA as an anticoagulant and centrifuged at 1,000 g within 30 min after collection. Biopsy specimens were mashed with a homogenizer, and the suspension was divided and used to determine IL-18 and protein concentrations. Samples were diluted 1:5 with 0.1 mol/L phosphate buffer before assay and stored at −20 °C. Samples were incubated at room temperature and assayed in duplicate with the quantitative sandwich enzyme immunoassay (EIA) technique using microtitre wells precoated with anti-human IL-18 antibodies (MBL, Nagoya, Japan). IL-18 remained in the microtitre wells after four cycles of washing and aspiration was detected by peroxidase-conjugated anti-human IL-18 specific antibodies. The amount of peroxidase bound to each well was determined by the optical density was read with a microtitre plate photometer Stat Fax® 2100 (Alab/Poland) at 450 nm. The concentration of IL-18 in sample was calibrated from a dose response curve based on reference standards. Mucosal IL-18 concentration was expressed as pg per mg of protein, which was measured by the Lowry method. According to a manufacturer’s sensitivity method. Samples were incubated at room temperature with 0.1 mol/L phosphate buffer before assay and stored at −20 °C. Samples were incubated at room temperature and assayed in duplicate with the quantitative sandwich enzyme immunoassay (EIA) technique using microtitre wells precoated with anti-human IL-18 antibodies (MBL, Nagoya, Japan). IL-18 remained in the microtitre wells after four cycles of washing and aspiration. IL-18 was detected by peroxidase-conjugated anti-human IL-18 specific antibodies. The amount of peroxidase bound to each well was determined by the absorbance measured at 450 nm with a microtitre plate photometer Stat Fax® 2100 (Alab/Poland). The concentration of IL-18 in sample was calibrated from a dose response curve based on reference standards. Mucosal IL-18 concentration was expressed as pg per mg of protein, which was measured by the Lowry et al. method. According to a manufacturer’s sensitivity method.

**Statistical analysis**

Values were expressed as mean±SE. The significance of differences was calculated by non-parametric Mann-Whitney U test. For correlation analysis, the Speraman non-parametric correlation was used. *P<0.05* was considered statistically significant.

**RESULTS**

The mean plasma concentration of IL-18 measured in all patients with active UC (422±88 pg/mL), but the difference was not statistically significant. There was no association between plasma IL-18 and the age of patients or the disease duration. The mucosal concentration of IL-18 varied from 83 to 6,239 pg/mg protein. As demonstrated in Table 1 among laboratory markers of inflammatory activity, only the mean values of CRP and SR exceeded the upper limit of normal range. However, a significant positive correlation (*r*=0.65, *P<0.05) was demonstrated only in respect to CRP values. Plasma IL-18 levels analyzed in all UC patients also revealed a significant positive correlation with scored endoscopic degree of mucosal injury, DAI and CAI values (Figure 1, Table 1). As shown in there was no association between mucosal concentration of IL-18 and clinical or laboratory signs of the disease activity. The mean concentration of plasma IL-18 was significantly higher in patients with severe UC (535±115 pg/mL) than in patients with mild UC (195±41 pg/mL), and in healthy controls (Figure 2). Although the mucosal mean IL-18 concentration in severe UC (2,523±618 pg/mg protein) doubled the values observed in mild UC (1,347±308 pg/mg protein), there was no statistically significant difference (Figure 3).

---

**Figure 1** Correlations between plasma concentrations of IL-18 and values of A: CAI (*r*=0.56, *P*=0.02); B: DAI (*r*=0.54, *P*=0.03); C: endoscopic score (*r*=0.62, *P*=0.01).

**Figure 2** Individual plasma IL-18 concentrations in healthy controls and UC patients with a mild or a severe form of the disease. Statistical significance between severe UC and mild UC as well as a control is indicated by arrows (*P*<0.05). Horizontal bar denotes the mean IL-18 concentration [pg/mL] in each of studied groups.

---

**Table 1** Laboratory and clinical markers of ulcerative colitis in analyzed patients

| Parameter        | Normal range | mean±SE | Correlation (r) |
|------------------|--------------|---------|-----------------|
|                  |              |         | plasma mucosal  |
| CRP [mg/dL]      | 0-5          | 18.5±4.8| 0.65* -0.13     |
| SR [mm/h]        | 0-5          | 23.1±5.0| 0.36 0.20       |
| WBC [×10³/μL]    | 4-10         | 6.8±0.6 | -0.08 0.06      |
| hemoglobin [mg/dL] | 12-18       | 13.2±0.3| -0.36 0.07      |
| fibrinogen [g/L] | 1.8–3.5      | 3.5±0.2 | 0.30 0.14       |
| albumin [g/L]    | 3.5–5.0      | 2.9±0.6 | -0.43 0.42      |
| protein [g/L]    | 6-8          | 5.8±0.2 | -0.29 0.31      |
| PLT [×10³/μL]    | 130-400      | 24±19.9 | -0.13 0.18      |
| albumin [g/L]    | 3.5–5.0      | 2.9±0.6 | -0.43 0.42      |
| protein [g/L]    | 6-8          | 5.8±0.2 | -0.29 0.31      |
| PLT [×10³/μL]    | 130-400      | 24±19.9 | -0.13 0.18      |
| CAI              | 0            | 10.7±0.7| 0.56* 0.47      |
| DAI              | 0            | 6.6±0.7 | 0.54* 0.29      |
| Endoscopic score | 0            | 3.0±0.2 | 0.62* 0.36      |

Correlations between plasma or mucosal concentrations of IL-18 and values of particular markers are demonstrated through (r) values. *P*<0.05, **P*<0.01.
DISCUSSION

Cytokines are the determinants of the nature of mucosal immune response. Development of IBD has been considered to be associated with the predominance of proinflammation over anti-inflammatory cytokines\(^{[2,17]}\). Animal models of experimental colitis exhibited clear differentiation toward Th1 or Th2 responses. CD4 T cells could produce predominant IL-2 and interferon-\(\gamma\), which are primarily involved in cellular immunity defined as Th1 response, whereas IL-4, IL-5 and IL-10 are predominantly produced by Th2 cells promoting humoral immunity\(^{[18,19]}\). Since it has been demonstrated by Seder et al\(^{[20]}\), that IL-4 and IL-10 could stimulate the production of transforming growth factor (TGF-\(\beta\)) by CD4+ cells, its increased concentration may also reflect Th2-mediated T cell response in UC patients. As we demonstrated recently plasma and mucosal concentrations of TGF-\(\beta\) were strongly associated with UC activity and successful treatment of the disease could result in a decrease of their levels\(^{[21]}\). In animal models, CD was predominantly related to Th1 immune response and Th2 immunity was responsible for UC development. In humans such a clear polarization of immune response in IBD pathogenesis was not observed\(^{[18,123]}\). According to Hoshino et al\(^{[22]}\) and Yoshimoto et al\(^{[20]}\), IL-18 was involved in both Th1 and Th2 responses in UC. A recent study by Matsuzaki et al\(^{[24]}\) demonstrated in UC patients the predominance of Th1 response in severe inflammation and Th2 in mild one. Moreover, Th1 response was associated with the degree of disease activity. Since Th2 response was observed in mildly inflamed mucosae, it seemed to be involved in the early phase of UC or the initiation of inflammation.

In this study, we demonstrated the elevation of plasma IL-18 in UC patients, which doubled the normal values without statistical significance. However, there was an evident association between plasma IL-18 concentrations and the disease activity evaluated through clinical and endoscopic scoring systems. Additionally there was a significant correlation between IL-18 values and CRP - an unspecific marker of inflammation. The association with UC activity was finally demonstrated in UC patients the predominance of Th1 response. Development of IBD has been considered to be associated with interleukin-18 concentrations in plasma but not in colonic mucosa. Plasma IL-18 can be considered a surrogate marker helpful in the evaluation of ulcerative colitis activity.

In conclusion, ulcerative colitis activity is strongly associated with interleukin-18 concentrations in plasma but not in colonic mucosa. Plasma IL-18 can be considered a surrogate marker helpful in the evaluation of ulcerative colitis activity.

**REFERENCES**

1. Beck PL, Podolsky DK. Growth factors in inflammatory bowel disease. *Inflamm Bowel Dis* 1999; 5: 44-60
2. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. *Gastroenterology* 1998; 115: 182-205
3. Zimmerman CM, Padgett RW. Transforming growth factor beta signaling mediators and modulators. *Gene* 2000; 249: 17-30
4. Wiercinska-Drapalo A, Jaroszewicz J, Flisiak R, Prokopowicz D. Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity. *World J Gastroenterol* 2003; 9: 2843-2845
5. McDonald SA, Palmen MJ, Van Rees EP, MacDonald TT. Characterization of the mucosal cell-mediated immune response in IL-2 knockout mice before and after the onset of colitis. *Immunology* 1997; 91: 73-80
6. McCormack G, Moriarty D, O’Donghue DP, McCormick PA, Sheahan K, Baird AW. Tissue cytokine and chemokine expression in inflammatory bowel disease. *Inflamm Res* 2001; 50: 491-495
7. Wiercinska-Drapalo A, Flisiak R, Prokopowicz D. Effect of ulcerative colitis activity on plasma concentration of transforming growth factor beta1. *Cytokine* 2001; 14: 343-346
8. Hoshino T, Kawase Y, Okamoto M, Yokota K, Yoshino K, Yamamura K, Miyazaki J, Young HA, Oizumi K. Cutting edge: IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function. *J Immunol* 2001; 166: 7014-7018
9. Yoshimoto T, Tsutsui H, Tominaga K, Hoshino K, Okamura H, Akira S, Paul WE, Nakashiba K. IL-18, although antiinflammatory when administered with IL-12, stimulates IL-4 and histamine release by basophils. *Proc Natl Acad Sci U S A* 1999; 96: 13962-13966
10. Ishikura T, Kanai T, Uraushihiara K, Iiyama R, Makita S, Totsuka T, Yamazaki M, Sawada T, Nakamura T, Miyata T, Kitahora T, Hibi T, Hoshino T, Watanabe M. Interleukin 18 overproduction exacerbates the development of colitis with markedly infiltrated macrophages in interleukin-18 transgenic mice. *J Gastroenterol Hepatol* 2003; 18: 960-969
11. Siegmund B, Fantuzzi G, Rieder F, Gamboni-Robertson F, Lehr HA, Hartmann G, Dinnarlov CA, Endres S, Eigel A. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. *Am J Physiol Regul Integr Comp Physiol* 2001; 281: R1264-R1273
12. Furuya D, Yagihashi A, Komatsu M, Masashi N, Tsuji N, Kobayashi D, Watanabe N. Serum interleukin-18 concentrations in patients with inflammatory bowel disease. *J Immunother* 2002; 25 Suppl 1: S65-S67
13. Meyers S, Sachar DB, Present DH, Janowitz HD. Olsalazine in the treatment of ulcerative colitis among patients intolerant of sulphasalazine: a prospective, randomized, placebo controlled double blind, dose-ranging clinical trial. *Scand J Gastroenterol Suppl* 1988; 148: 29-37
14 Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *N Engl J Med* 1987; 317: 1625-1629

15 Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. *Br Med J* 1955; 9: 1041-1048

16 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem* 1951; 193: 265-275

17 Bode H, Schmitz H, Fromm M, Scholz P, Riecken EO, Schulzke JD. IL-1beta and TNF-alpha, but not IFN-alpha, IFN-gamma, IL-6 or IL-8, are secretory mediators in human distal colon. *Cytokine* 1998; 10: 457-465

18 Neurath MF, Finotto S, Glimcher LH. The role of Th1/Th2 polarization in mucosal immunity. *Nat Med* 2002; 8: 567-573

19 Monteleone I, Vavassori P, Biancone L, Monteleone G, Pallone F. Immunoregulation in the gut: success and failures in human disease. *Gut* 2002; 50 Suppl 3: III60-III64

20 Seder RA, Marth T, Sieve MC, Strober W, Letterio JJ, Roberts AB, Kelsall B. Factors involved in the differentiation of TGF-beta producing cells from naive CD4+ T cells: IL-4 and IFN-gamma have opposing effects, while TGF-beta positively regulates its own production. *J Immunol* 1998; 160: 5719-5728

21 Wiercinska-Drapalo A, Flisiak R, Prokopowicz D. Effect of ulcerative colitis treatment on transforming growth factor beta (1) in plasma and rectal mucosa. *Regul Pept* 2003; 113: 57-61

22 Hoshino T, Yagita H, Ortaldo JR, Willtrout RH, Young HA. *In vivo* administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4 T cells. *Eur J Immunol* 2000; 30: 1998-2006

23 Sawa Y, Oshitani N, Adachi K, Higuchi K, Matsumoto T, Arakawa T. Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease. *Int J Mol Med* 2003; 11: 175-179

24 Matsuzaki K, Hokari R, Kato S, Tsuzuki Y, Tanaka H, Kurihara C, Iwai A, Kawaguchi A, Nagao S, Itoh K, Nagata K, Miura S. Differential expression of CCR5 and CRTH2 on infiltrated cells in colonic mucosa of patients with ulcerative colitis. *J Gastroenterol Hepatol* 2003; 18: 1081-1088

Assistant Editor Guo SY  Edited by Wang XL